KRAS and colorectal carcinoma: The ability of voruciclib to inhibit tumor growth in vivo was also tested in murine xenograft models injected separately with KRAS mutant CRC, NSCLC primary human cancer cells, wherein significant tumor growth inhibition (>50%) was observed at all doses of voruciclib [92].